PDL BioPharma — Shareholder Meeting (June 2018)
25 slides from PDL BioPharma's shareholder meeting presentation, Jun 8, 2018
Slide 1: Annual Meeting of Stockholders
PDL Annual Meeting of Stockholders June 8, 2018 PDL BioPharma, Inc. Nasdaq: PDLI
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements including PDL's expectations with respect to its future royalty revenues, expenses, net income and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actual
Slide 3: Governance Recommendations
Governance Recommendations a Re-elect Jody Lindell Re-elect John McLaughlin Elect Shlomo Yanai Ratify appointment of PWC as PDL’s auditors Approve on an advisory basis executive officers’ compensation Approve Amended and Restated Equity Plan For For For For For For For For For For For For
Slide 4: Corporate Governance Scores
Corporate Governance Scores Periodically, ISS Corporate Solutions assesses each public company with an overall “Quality Score” based on corporate governance metrics. ISS Governance Quality Score 5 Board Structure 4 Compensation 8 Shareholder Rights 4 Audit 2. 3 5 2 4 2
Slide 5: PDL's Strategy
PDL’s Strategy Maximize shareholder value through the acquisition, nurturing and monetization of a portfolio of healthcare companies. Strategic focus on developing and capturing the value of a growing portfolio of operating companies: + Noden Pharma DAC, a specialty pharma company domiciled in Irela
Slide 6: Investment Highlights
Investment Highlights Noden Pharma has built an efficient, global commercial structure for the commercialization of cardiovascular and primary care products. - Generating profitable cash flows with Tekturna®/Rasilez®, leveraging recently stabilized U.S. Rx trends and well-targeted international mark
Slide 7: Leadership with Proven Track Record
Leadership with Proven Track Record Executive Management Capabilities & Accomplishments John McLaughlin, CEO * $1 billion in completed transactions Dominique Monnet, President Muitiplesuccesstulll0s * Commercial productlaunches and Geter Cateig CFO. growth in the US and internationally Shriststoners
Slide 8: Noden Pharma
PDL NODEN y PHARMA
Slide 9: The Noden Transaction
The Noden Transaction ¢ Noden Pharma and Tekturna®/Rasilez® were PDL’s first operational acquisitions under its new business strategy. ¢ Total Tekturna®/Rasilez® potential purchase price from Novartis is up to $294 million. - $110 million paid at closing in July 2016 and $89 million paid at first an
Slide 10: Current Noden Products
Current Noden Products ws SNES) SS BSS5 Tekturna® (U.S.), Rasilez® (ex-U.S.) — contain aliskiren, the first and only approved direct renin inhibitor for the management of hypertension. = Not for use with ACE inhibitors or ARBs in patients with diabetes or renal impairment, pregnant women and pediatr
Slide 11: The Tekturna Opportunity
The Tekturna® Opportunity Hypertension is a chronic condition with serious long-term health implications, affecting nearly 50% of all adults in the U.S.1 Angiotensin Converting Enzyme Inhibitors (ACEIs) and Angiotensin Il Receptor Blockers (ARBs) are typically first- and second-line therapies. Tektu
Slide 12: Executing Well Targeted Promotion
Executing Well Targeted Promotion ACE/ ARB Intolerant: SWITCH CCB Notat Goal: ADD Estimated 3.3 million patients Estimated 6 million patients
Slide 13: Tekturna/Rasilez Intellectual Property
Tekturna®/Rasilez® Intellectual Property + United States - Composition-of-matter protection to 2018 for Tekturna®; listed in the Orange Book; — Plus 6-month extension from successful completion of pediatric testing requirements. ~ Composition-of-matter protection until 2022 for Tekturna® HCT. ~ Form
Slide 14: LENSAR
PDL CATARACT LASER WITH AUGMENTED REALTY
Slide 15: LENSAR
| LENSAR Converted debt to equity in May 2017. - $119 million in NOLs available. - To consider an exit when shareholder value is maximized. Leading global developer and manufacturer of femtosecond cataract lasers (FLS) for cataract surgery. Cataract surgery is the No. 1 surgical procedure globally b
Slide 16: Royalty and Debt Portfolio
PDL Royalty and Debt Portfolio
Slide 17: Concluded Royalty and Debt Investments
Concluded Royalty and Debt Investments Generated 15.9% IRR RovaltyTransaction | [ Rovalt-Acauisitin | | SenlorSecured Senior Secured Royalty Transaction Senior Secured Tinaneing Financing Senor Secured Tinaneing Financing Financing Welt Signsis, LUC 3XK Depomed AR LENSAR DURATA @ axoGen MERUS LABS e
Slide 18: Cash Flow Funds the New Business Strategy
Cash Flow Funds the New Business Strategy: $19.3 million in Q1-2018 indefinite i 6/2018 Bi \ Ome fi 5/2026 p) $240.5M $325.4M > janssen (9/2023 Br | Qi! a, 12/2026 ll J = Payoff $100.0M — $120.0M? “ARIAD ice . 4/2022 $65.6M $9.2M cave: S SANOFI GENZYME ZALVISO” 1/2032 $65.0M $0.2M Sura SE aceD ELEY
Slide 19: Financials
PDL Financials
Slide 20: First Quarter 2018 Income Statement
First Quarter 2018 Income Statement Three Months Ended Interest and other income, net Income tax expense Net loss attributable to noncontroliing interests Net income attributable to PDL's shareholders Net income per share - Basic Net income per share - Diluted March 31, (in thousands, except per sha
Slide 21: Strong Balance Sheet
Strong Balance Sheet ($ in millions) Cash, cash equivalents and short-term investments $405 Total Assets $1,100 Debt: 2.75% Convertible Debt — due 12/2021 ($3.81 conversion price)? $150 1) PDLentered into a capped call transaction to offset potential dilution subject to a cap of $4.88. PDL
Slide 22: Share Repurchase Program
Share Repurchase Program « While our focus is on the strategic acquisition of biopharma assets, given the significant discount of PDL’s stock price to its book value, we have implemented share repurchase programs to return value to shareholders. ¢ Current Program — $25 Million - In September 2017 PD
Slide 23: A History of Value Creation
A History of Value Creation Book value per share reached $5.60 as of Mar PDL's Book Value Per Share” a oO SPRPENNNNUWUW ERENT D REASRSASRSASRSASRSasRSas 2 8 3 & & 2°23 a2 2 8 8 8 5 5 & & 8 @ 8 & §€ ¢@ & § @ & € @ @ § € &@ B&B §& § & ¢ 8 8 2 3 &§ 328 86 3 #8 & 8 (1) Does not include asset value of ro
Slide 24: High-Quality Asset Value
High-Quality Asset Value Assets 1200 Balance 3/31/2018 1000 Selected Component $ millions Per Share 800 Royalty Rights $ 3417 $ 227 Noden & LensarBook Value $ 213.2 $ 142 600 Notes Receivable $70.7 $0.47 Total Investments $ 625.6 $ 4.16 400 EE Cosh $405.1 $2.69 200 Debt $ (150.0) $ (1.00) Net Cash $
Slide 25: Why Invest in PDLI?
Why Invest in PDLI? Highlights Tekturna ® and Rasilez® are important products for treating hypertension and Noden investment was immediately cash flow accretive to PDL Lensar is a smart investment in a leading technology in a large and growing market with $119 million _ in NOLs available. Nine activ